Exhibit 99.1
| Press Release |  |
| www.shire.com | |
Directorate change
February 15, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces the following changes to Board committee membership, effective immediately:
| Director | Appointment | Resignation |
| Dominic Blakemore | Remuneration Committee | N/A |
| Olivier Bohuon | Nomination & Governance Committee | Science & Technology Committee |
| Ian Clark | Remuneration Committee; Science & Technology Committee | N/A |
| Sara Mathew | Nomination & Governance Committee | Remuneration Committee |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | | |
| Ian Karp | ikarp@shire.com | +1 781 482 9018 |
| Robert Coates | rcoates@shire.com | +44 1256 894874 |
| Media | | |
| Lisa Adler | lisa.adler@shire.com | +1 617 588 8607 |
| Debbi Ford | debbi.ford@shire.com | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
